Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...

Fintel reports that on January 6, 2025, Cantor Fitzgerald initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Overweight ...

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including ...

Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com ...

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...

For patients undergoing breast reconstruction after mastectomy, age impacts surgical outcomes, with older age negatively ...

Efzofitimod is under clinical development by aTyr Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

For patients undergoing breast reconstruction after mastectomy, age impacts surgical outcomes, with older age negatively ...

If you want to know who really controls aTyr Pharma, Inc. (NASDAQ:ATYR), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...